Compositions and methods for transdermal oxybutynin therapy

Details Compositions and methods for transdermal oxybutynin therapy Compositions and methods for transdermal oxybutynin therapy

2007-02-20

2007-02-20

Ghali, Isis (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Web, sheet or filament bases; compositions of bandages; or...

C424S448000, C424S443000

Reexamination Certificate

active

10913019

ABSTRACT:
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.

REFERENCES:
patent: 4652441 (1987-03-01), Okada et al.
patent: 4959217 (1990-09-01), Sanders et al.
patent: 5028430 (1991-07-01), Sanders et al.
patent: 5152997 (1992-10-01), Ebert et al.
patent: 5164190 (1992-11-01), Patel et al.
patent: 5212199 (1993-05-01), Heiber et al.
patent: 5227169 (1993-07-01), Heiber et al.
patent: 5411740 (1995-05-01), Lee et al.
patent: 5500222 (1996-03-01), Lee et al.
patent: 5516808 (1996-05-01), Sawaya
patent: 5532278 (1996-07-01), Aberg et al.
patent: 5575987 (1996-11-01), Kamei et al.
patent: 5582838 (1996-12-01), Rork et al.
patent: 5601839 (1997-02-01), Quan et al.
patent: 5614211 (1997-03-01), Gale et al.
patent: 5626866 (1997-05-01), Ebert et al.
patent: 5641504 (1997-06-01), Lee et al.
patent: 5643584 (1997-07-01), Farng et al.
patent: 5674895 (1997-10-01), Guittard et al.
patent: 5677346 (1997-10-01), Aberg et al.
patent: 5721275 (1998-02-01), Bazzano
patent: 5736577 (1998-04-01), Aberg et al.
patent: 5747065 (1998-05-01), Lee et al.
patent: 5759583 (1998-06-01), Iwamoto et al.
patent: 5762953 (1998-06-01), Venkateshwaran
patent: 5783208 (1998-07-01), Venkateshwaran et al.
patent: 5840754 (1998-11-01), Guittard et al.
patent: 5891462 (1999-04-01), Carrara
patent: 5891920 (1999-04-01), Hirano et al.
patent: 5900250 (1999-05-01), Lee et al.
patent: 5912268 (1999-06-01), Guittard et al.
patent: 5922342 (1999-07-01), Shah et al.
patent: 5939094 (1999-08-01), Durif et al.
patent: 5948433 (1999-09-01), Burton et al.
patent: 5972369 (1999-10-01), Roorda et al.
patent: 5985305 (1999-11-01), Peery et al.
patent: 5985317 (1999-11-01), Venkateshwaran et al.
patent: 6039967 (2000-03-01), Ottoboni et al.
patent: 6096339 (2000-08-01), Ayer et al.
patent: 6187323 (2001-02-01), Aiache et al.
patent: 6203817 (2001-03-01), Cormier et al.
patent: 6258830 (2001-07-01), Charu
patent: 6319913 (2001-11-01), Mak et al.
patent: 6562368 (2003-05-01), Hsu et al.
patent: 2001/0031787 (2001-10-01), Hsu et al.
patent: 2002/0147236 (2002-10-01), Sanders et al.
patent: 2002/0161044 (2002-10-01), Sherratt et al.
patent: WO 92/10231 (1992-06-01), None
patent: WO 92/20377 (1992-11-01), None
patent: WO 93/23025 (1993-11-01), None
patent: WO 95/-09007 (1995-04-01), None
patent: WO 99/48493 (1999-09-01), None
patent: WO 99/48494 (1999-09-01), None
L. Noronha-Blob and J.F. Kachur, Enantiomers of Oxybutynin:In VitroPharmacological Characterization at M1, M2and M3Muscarinic Receptors andin VivoEffects on Urinary Bladder Contraction, Mydriasis and Salivary Secretion in Guinea Pigs,Journal of Pharmacology and Experimental Therapeutics, 256: 562-567, (1990).
Ernest W. Merritt and Eugene R. Cooper,Diffusion Apparatus for Skin Penetration, Journal of Controlled Release, 1: 161-162, (1984).
James F. Kchur, Jan s. Peterson, J. Paul Carter, W. Janusz Rzeszotarksi, Robert C. Hanson and Lalita Noronha-Blob,R and S Enantiomers of Oxybutynin: Pharmacological Effects in Guinea Pig Bladder and Intestine, The Journal of Pharmacology and Experimental Therapeutics, 247: 3,867-872, (1988).
Buyse, Gunnar et al., “Intravesical Oxybutynin for Neurogenic Bladder Dysfunction: Less Systemic Side Effects Due to Reduced first Pass Metabolism,” The Journal of Urology, Sep. 1998, pp. 892-896, vol. 160.
Gupta, Suneel K. (PH.D) et al., “Pharmacokinetics of an Oral Once-a-Day Controlled-Release Oxybutynin Formulation Compared with Immediate-Release Oxybutynin,” J. Clin. Pharmacol, 1999, pp. 289-296, vol. 39.

Affiliated with

Also associated with

Rating

Compositions and methods for transdermal oxybutynin therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for transdermal oxybutynin therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for transdermal oxybutynin therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3893743